In a nutshell The study aimed to investigate the health-related quality of life (HR-QoL) for patients with chronic lymphocytic leukemia (CLL) who were treated with venetoclax (VEN; Venclexta) and obinutuzumab (Obi; Gazyva). This study concluded that this treatment is effective and does not impair the quality of life in these...
Read More
In a nutshell This study aimed to investigate the long-term outcomes for children with acute myeloid leukemia (AML) who were treated with low-dose chemotherapy (LDC). This study concluded that there is a high remission rate for these patients and that long-term survival is similar to patients who...
Read More
In a nutshell This study aimed to investigate minimal residual disease (MRD) levels on the outcomes of children with very low-risk (VLR) acute lymphoblastic leukemia (ALL) treated with reduced intensity therapy. This study concluded that patients who had a low level of MRD had good outcomes with reduced intensity...
Read More
In a nutshell This study aimed to investigate if blinatumomab was an effective treatment in patients with minimal residual disease B-cell precursor acute lymphoblastic leukemia. This study concluded that complete minimal residual response during blinatumomab treatment can be a potentially...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of the combination of all-trans-retinoic acid (Vesanoid), arsenic trioxide (Trisenox), and idarubicin (Idamycin) as front-line treatment for acute promyelocytic leukemia. This study concluded that this combination is safe and effective for these...
Read MoreIn a nutshell This study aimed to investigate the long-term outcomes for patients with acute myeloid leukemia who received reduced-intensity conditioning and allogeneic stem cell transplant. This study concluded that this treatment is safe and effective in these patients in the long-term. Some background One of the standard...
Read MoreIn a nutshell This study examined the major factors associated with disease progression and outcomes in adults with acute myeloid leukemia (AML). The authors found that younger age, less molecular mutations and choice of induction therapy were all positively associated with higher rates of complete remission and survival. Some background A number...
Read More
In a nutshell This study looked at the effect of neutrophil recovery time (NRT – the return of white blood cells after treatment, that fight infection) on infections and relapse (return of disease) in children with acute myeloid leukaemia (AML). The study found that longer NRT was linked with increased risk of severe infections and relapse after...
Read More
In a nutshell This study examined lenalidomide (Revlimid) as a consolidation strategy in patients with chronic lymphocytic leukemia (CLL) who have residual disease after treatment. This study reported good response improvements (in 45% of patients with residual disease). Lenalidomide may be particularly suited as a consolidation strategy after...
Read More
In a nutshell This study aimed to investigate the safety and efficacy of bortezomib (Velcade) when combined with induction chemotherapy in Japanese children with refractory acute lymphoblastic leukemia. This study concluded that the combination of bortezomib and induction chemotherapy has high effectiveness but led to a high risk of infectious...
Read More
In a nutshell This study, from 2009, examined the effectiveness of increasing the dose of daunorubicin (Cerubidine) in acute myeloid leukemia (AML). This study concluded that a higher dose improved remission rates (no sign of disease) and 2-year survival rates. Some background The standard induction therapy (treatment to induce remission) for AML...
Read More
